Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 09:19 am Sale | 2023-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | Lynx1 Capital Management LP | 46 0.100% | -114,511 (-99.96%) | Filing History |
| 2023-12-27 4:03 pm Purchase | 2023-12-18 | 13G | Neurogene Inc. NGNE | GREAT POINT PARTNERS LLC | 969,229 7.560% | 969,229 (New Position) | Filing History |
| 2023-12-22 4:15 pm Purchase | 2023-12-18 | 13G | Neurogene Inc. NGNE | Redmile Group LLC | 1,282,661 9.900% | 1,282,661 (New Position) | Filing History |
| 2023-12-21 4:05 pm Purchase | 2023-12-18 | 13D | Neurogene Inc. NGNE | McMinn Rachel | 1,273,351 9.900% | 1,273,351 (New Position) | Filing History |
| 2023-12-20 5:24 pm Purchase | 2023-12-18 | 13D | Neurogene Inc. NGNE | BAKER BROS ADVISORS LLC | 649,685 4.990% | 649,685 (New Position) | Filing History |
| 2023-10-10 4:42 pm Purchase | 2023-10-05 | 13D | Neoleukin Therapeutics, Inc. NLTX | BAKER BROS ADVISORS LLC | 473,667 19.990% | 473,667 (New Position) | Filing History |
| 2023-08-17 5:12 pm Sale | 2023-08-15 | 13D | Neoleukin Therapeutics, Inc. NLTX | BAKER BROS ADVISORS LLC | 473,605 19.990% | -28,549 (-5.69%) | Filing History |
| 2023-07-27 5:15 pm Sale | 2023-07-17 | 13D | Neoleukin Therapeutics, Inc. NLTX | Redmile Group LLC | 145,611 6.600% | -5,917 (-3.90%) | Filing History |
| 2023-07-19 5:28 pm Purchase | 2023-07-17 | 13D | Neoleukin Therapeutics, Inc. NLTX | BAKER BROS ADVISORS LLC | 502,154 19.990% | 290,663 (+137.43%) | Filing History |
| 2023-02-14 4:21 pm Sale | 2022-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | Redmile Group LLC | 151,528 6.900% | -64,550 (-29.87%) | Filing History |
| 2023-02-03 11:56 am Sale | 2022-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | PICTET ASSET MANAGEMENT SA | 0 0.000% | -128,714 (Position Closed) | Filing History |
| 2023-01-19 4:10 pm Sale | 2022-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | MILLENNIUM MANAGEMENT LLC | 79,363 3.700% | -27,266 (-25.57%) | Filing History |
| 2022-12-30 4:29 pm Purchase | 2022-12-20 | 13G | Neoleukin Therapeutics, Inc. NLTX | Lynx1 Capital Management LP | 114,557 5.380% | 114,557 (New Position) | Filing History |
| 2022-07-19 4:08 pm Purchase | 2022-07-18 | 13G | Neoleukin Therapeutics, Inc. NLTX | MILLENNIUM MANAGEMENT LLC | 106,629 5.000% | 1,058 (+1.00%) | Filing History |
| 2022-07-15 4:04 pm Sale | 2022-07-07 | 13G | Neoleukin Therapeutics, Inc. NLTX | MILLENNIUM MANAGEMENT LLC | 105,571 4.970% | -269 (-0.25%) | Filing History |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Neoleukin Therapeutics, Inc. NLTX | BlackRock Inc. BLK | 45,542 2.100% | -84,691 (-65.03%) | Filing History |
| 2022-07-07 4:56 pm Purchase | 2022-06-27 | 13G | Neoleukin Therapeutics, Inc. NLTX | MILLENNIUM MANAGEMENT LLC | 105,840 4.980% | 105,840 (New Position) | Filing History |
| 2022-02-14 5:07 pm Purchase | 2021-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | Redmile Group LLC | 216,078 9.900% | 6,295 (+3.00%) | Filing History |
| 2022-02-14 3:03 pm Sale | 2021-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | EcoR1 Capital LLC | 43,031 2.000% | -113,104 (-72.44%) | Filing History |
| 2022-02-11 4:06 pm Sale | 2021-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | Silva Manzano Daniel Adriano | 145,458 6.800% | -1,449 (-0.99%) | Filing History |